Payment overview · 2025
General Payments
$328.60
10 reported records · 10 companies
Healthcare provider profile · identity verified
Scott Q Carver
Allopathic & Osteopathic Physicians|Family Medicine · SARALAND, AL · NPI 1023112257
Verified facts
What the public records show
CMS Open Payments records show Scott Q Carver received $328.60 in general payments during 2025 across 10 reported records.
Atland Pharmaceuticals, LLC accounted for 49.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 350 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Atland Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $164.10 | 49.9% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $28.53 | 8.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.71 | 7.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.73 | 6.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.17 | 5.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.19 | 5.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.30 | 4.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.05 | 4.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.64 | 4.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.18 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $328.60 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE Normalized: orphenadrine citrate aspirin and caffeine |
Drug | Atland Pharmaceuticals, LLC | $164.10 | 1 | 2025 |
Source payment records
|
|||||
| TOLMETIN SODIUM Normalized: tolmetin sodium |
Drug | Atland Pharmaceuticals, LLC | $164.10 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $28.53 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 21 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 132 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
21 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
350 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 800 | 198 |
| Amlodipine Besylate | Amlodipine Besylate | 677 | 166 |
| Levothyroxine Sodium | Levothyroxine Sodium | 531 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 405 | 117 |
| Furosemide | Furosemide | 392 | 82 |
| Lisinopril | Lisinopril | 366 | 95 |
| Eliquis | Apixaban | 350 | 43 |
| Gabapentin | Gabapentin | 345 | 84 |
| Losartan Potassium | Losartan Potassium | 340 | 79 |
| Metformin Hcl | Metformin Hcl | 340 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 324 | 85 |
| Potassium Chloride | Potassium Chloride | 285 | 63 |
| Carvedilol | Carvedilol | 276 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 264 | 68 |
| Sertraline Hcl | Sertraline Hcl | 240 | 37 |
| Omeprazole | Omeprazole | 224 | 67 |
| Tramadol Hcl | Tramadol Hcl | 213 | 61 |
| Trazodone Hcl | Trazodone Hcl | 213 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 207 | 45 |
| Montelukast Sodium | Montelukast Sodium | 198 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 187 | 49 |
| Allopurinol | Allopurinol | 184 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 173 | 37 |
| Jardiance | Empagliflozin | 167 | 43 |
| Meloxicam | Meloxicam | 167 | 45 |
| Mounjaro | Tirzepatide | 161 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 158 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 58 |
| Simvastatin | Simvastatin | 147 | 41 |
| Cefdinir | Cefdinir | 143 | 124 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 37 |
| Alprazolam | Alprazolam | 133 | 24 |
| Ozempic | Semaglutide | 132 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 122 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 120 | 13 |
| Donepezil Hcl | Donepezil Hcl | 116 | 21 |
| Buspirone Hcl | Buspirone Hcl | 115 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 36 |
| Mirtazapine | Mirtazapine | 110 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 31 |
| Ibuprofen | Ibuprofen | 103 | 27 |
| Memantine Hcl | Memantine Hcl | 103 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 27 |
| Sucralfate | Sucralfate | 90 | 16 |
| Divalproex Sodium | Divalproex Sodium | 89 | suppressed |
| Ezetimibe | Ezetimibe | 89 | 23 |
| Lorazepam | Lorazepam | 88 | 14 |
| Famotidine | Famotidine | 86 | 31 |
| Levetiracetam | Levetiracetam | 86 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 82 | 75 |
| Atenolol | Atenolol | 81 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 17 |
| Risperidone | Risperidone | 79 | suppressed |
| Olanzapine | Olanzapine | 78 | 15 |
| Levofloxacin | Levofloxacin | 77 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 18 |
| Ceftriaxone | Ceftriaxone Sodium | 74 | 29 |
| Glipizide | Glipizide | 74 | 21 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 73 | 19 |
| Clonidine Hcl | Clonidine Hcl | 72 | 23 |
| Metformin Hcl Er | Metformin Hcl | 72 | 18 |
| Latanoprost | Latanoprost | 71 | 11 |
| Alendronate Sodium | Alendronate Sodium | 70 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 67 | 13 |
| Warfarin Sodium | Warfarin Sodium | 64 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 62 | suppressed |
| Prednisone | Prednisone | 59 | 25 |
| Austedo | Deutetrabenazine | 58 | suppressed |
| Baclofen | Baclofen | 58 | 12 |
| Chlorthalidone | Chlorthalidone | 55 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 15 |
| Spironolactone | Spironolactone | 55 | 16 |
| Clonazepam | Clonazepam | 54 | 19 |
| Fluconazole | Fluconazole | 52 | 30 |
| Nebivolol Hcl | Nebivolol Hcl | 52 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | suppressed |
| Novolin R | Insulin Regular, Human | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 48 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 14 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 25 |
| Lidocaine Hcl | Lidocaine Hcl | 43 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Colchicine | Colchicine | 39 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 39 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 15 |
| Linzess | Linaclotide | 38 | 15 |
| Mupirocin | Mupirocin | 38 | 27 |
| Phenobarbital | Phenobarbital | 38 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 38 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 37 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Fentanyl | Fentanyl | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 18 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Glipizide Er | Glipizide | 36 | 12 |
| Irbesartan | Irbesartan | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | 11 |
| Topiramate | Topiramate | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Livalo | Pitavastatin Calcium | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 35 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | 13 |
| Azithromycin | Azithromycin | 34 | 26 |
| Benztropine Mesylate | Benztropine Mesylate | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Ketoconazole | Ketoconazole | 34 | 11 |
| Levemir | Insulin Detemir | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | 11 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Lubiprostone | Lubiprostone | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Piroxicam | Piroxicam | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Humulin R | Insulin Regular, Human | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 20 |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 22 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | 11 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 22 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 21 | 20 |
| Gentamicin Sulfate | Gentamicin Sulfate | 21 | 20 |
| Lacosamide | Lacosamide | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | 11 |
| Valacyclovir | Valacyclovir Hcl | 21 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Novolog | Insulin Aspart | 20 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 20 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 20 | 20 |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 13 |
| Diazepam | Diazepam | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 13 |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Nadolol | Nadolol | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Nystatin | Nystatin | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Tivicay | Dolutegravir Sodium | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Procrit | Epoetin Alfa | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Risperidone Er | Risperidone Microspheres | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $328.60 · 10 records | Atland Pharmaceuticals, LLC | ABRYSVO, COMIRNATY, FREESTYLE LIBRE 3, INJECTAFER, LEQVIO, ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE, Ozempic, PREVNAR 20, Rybelsus, TOLMETIN SODIUM, VOQUEZNA, VRAYLAR, XIFAXAN, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error